Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

Aker Solutions has delivered high revenue growth and a strong order intake in the first quarter of 2025. The company continues to have a ...

Link11, DOSarrest, and Reblaze have combined their strengths into a single, integrated platform with a new brand identity. The result: ...

Elkem's EBITDA for the first quarter 2025 was NOK 898 million, up from NOK 721 million in the corresponding quarter last year. The ...